These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 15207780)

  • 1. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor.
    Eriksson K; Sun JB; Nordström I; Fredriksson M; Lindblad M; Li BL; Holmgren J
    Eur J Immunol; 2004 May; 34(5):1272-81. PubMed ID: 15114660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
    He T; Tang C; Xu S; Moyana T; Xiang J
    Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
    J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A; Snyder D; Gilboa E
    J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
    Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
    Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
    J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
    Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine dendritic cells generated under serum-free conditions have a mature phenotype and efficiently induce primary immune responses.
    Warncke M; Dodero A; Dierbach H; Follo M; Veelken H
    J Immunol Methods; 2006 Mar; 310(1-2):1-11. PubMed ID: 16337648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
    Met O; Wang M; Pedersen AE; Nissen MH; Buus S; Claesson MH
    Cancer Lett; 2006 Jan; 231(2):247-56. PubMed ID: 16399226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L; Sad S; Patel GB; Sprott GD
    Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S; Darrow TL; Vervaert CE; Seigler HF
    Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.